Biogen (BIIB) - Company Research
Last Updated: 26 April 2026
Biogen (NASDAQ: BIIB) sits at one of the most consequential inflection points in its 47-year history. The legacy multiple sclerosis franchise – once the entire identity of the company – is shrinking under generic and biosimilar pressure, while a new portfolio anchored by Leqembi in Alzheimer’s, Skyclarys in Friedreich’s ataxia, Zurzuvae in postpartum depression and Qalsody in SOD1-ALS now contributes roughly a third of revenue and is growing at double-digit rates. On 31 March 2026 Biogen agreed to acquire Apellis Pharmaceuticals for approximately $5.6 billion, doubling down on rare disease and immunology and expanding into nephrology and ophthalmology. With Q1 2026 results due on 29 April 2026, this report covers the financials, the pipeline, the competitive set against Eli Lilly’s Kisunla in Alzheimer’s, and the principal risks investors are weighing.
1. Company Snapshot
| Company | Biogen Inc. |
| Ticker | NASDAQ: BIIB |
| Sector / Industry | Healthcare – Biotechnology / Drug Manufacturers |
| Headquarters | Cambridge, Massachusetts, USA |
| CEO | Christopher Viehbacher (since November 2022) |
| CFO | Robin Kramer (EVP & CFO since March 2025) |
| Founded | 1978 (Biogen) / 2003 merger with Idec Pharmaceuticals |
| Employees | ~7,000 (post Fit for Growth restructuring) |
| Share price (24 Apr 2026) | $184.38 |
| 52-week range | $115.25 – $202.41 |
| Market cap | ~$27.1 bn |
| Net debt (31 Dec 2025) | ~$2.0 bn (cash $4.2 bn / debt $6.3 bn) |
| FY 2025 revenue | $9.89 bn (+2% YoY) |
| FY 2025 Non-GAAP EPS | $15.28 |
| FY 2026 guidance | Revenue down mid-single-digit %; Non-GAAP EPS $15.25–$16.25 |
| Dividend | None – capital returned via buybacks/M&A |
| Next earnings | Q1 2026 results – 29 April 2026 (pre-market) |
2. Bull Case vs Bear Case
| Bull Case | Bear Case |
|---|---|
| Growth products (Leqembi, Skyclarys, Zurzuvae, Qalsody) grew 19% in 2025 to ~$3.3 bn and now represent ~33% of revenue, with a clear path to majority of revenue by 2027. | Legacy MS franchise (Tecfidera, Tysabri, Avonex, Plegridy) collectively ~$3.3 bn in 2025 and declining ~7% per year – offsetting growth product gains and producing flat-to-down headline revenue. |
| Leqembi global in-market sales reached ~$134 m in Q4 2025 (+54% YoY) with subcutaneous IQLIK formulation and CMS coverage broadening; Eisai/Biogen retain ~60% U.S. anti-amyloid share. | Eli Lilly’s Kisunla, with monthly dosing and a defined treatment-stop option, hit $109 m in Q4 2025 and is taking share at the launch margin; some analysts now cite Kisunla as the U.S. prescription leader. |
| Apellis acquisition ($5.6 bn, closing Q2 2026) adds $689 m of 2025 revenue from Empaveli (rare kidney/PNH) and Syfovre (geographic atrophy) growing mid-to-high teens, plus a U.S. nephrology sales force ready for felzartamab. | The Apellis premium of ~140% over the unaffected price plus $4 CVR raises integration and goodwill-impairment risk; Biogen’s post-deal leverage rises sharply. |
| Diversified late-stage pipeline: BIIB080 (tau ASO, Phase 2 readout mid-2026), salanersen (next-gen SMA), dapirolizumab (lupus, Phase 3 positive), litifilimab, and felzartamab in three Phase 3 indications. | Spinraza global revenue fell to $1.55 bn in 2025 (Q4 down 15% YoY) under pressure from Roche’s oral Evrysdi and Novartis’s Zolgensma; the high-dose regimen approval (March 2026) is a defensive move. |
| “Fit for Growth” restructuring on track to deliver ~$1 bn gross / ~$800 m net savings; FY 2025 free cash flow $2.1 bn; valuation modest at ~7× EV/EBITDA and ~10× trailing P/E. | 2026 guidance still implies a mid-single-digit revenue decline before Apellis contribution; the “new Biogen” thesis depends on multiple binary clinical readouts in 2026–2027. |
3. What Does This Company Actually Do?
Biogen is a US biotechnology company that discovers, develops and commercialises therapies for serious neurological, rare and immune-mediated diseases. Its commercial portfolio is now best understood in three buckets: a declining multiple sclerosis franchise, a growing rare-disease franchise, and a launch portfolio anchored by Leqembi in Alzheimer’s.
FY 2025 revenue mix (total $9.89 bn):
| Franchise / Product | FY 2025 revenue | % of total |
|---|---|---|
| Multiple Sclerosis (total) | ~$4.04 bn | ~41% |
| Tysabri (natalizumab) | ~$1.67 bn | 17% |
| Vumerity (diroximel fumarate) | ~$747 m | 8% |
| Avonex / Plegridy (interferons) | ~$946 m | 10% |
| Tecfidera (dimethyl fumarate) | ~$680 m | 7% |
| Rare disease (total) | ~$2.15 bn | ~22% |
| Spinraza (nusinersen, SMA) | ~$1.55 bn | 16% |
| Skyclarys (omaveloxolone, FA) | ~$521 m | 5% |
| Qalsody (tofersen, SOD1-ALS) | ~$87 m | 1% |
| Biosimilars (Benepali, Imraldi, Flixabi) | ~$729 m | 7% |
| Contract manufacturing & royalties (Ocrevus, Rituxan) | ~$733 m | 7% |
| Zurzuvae (zuranolone, postpartum depression) | ~$195 m | 2% |
| Leqembi (lecanemab, Alzheimer’s – Biogen share) | ~$178 m | 2% |
| Other (Aduhelm, Fumaderm) | ~$90 m | 1% |
4. The Business Model
Biogen runs the classic high-gross-margin biotech model. FY 2025 Non-GAAP cost of sales was ~21% of revenue, implying a Non-GAAP gross margin of ~79%. R&D was ~$1.73 bn (Non-GAAP), and SG&A ~$2.42 bn, giving a Non-GAAP operating margin in the low-to-mid 30% range.
Revenue is generated from four channels:
- Wholly-owned in-market sales – Tysabri, Tecfidera, Vumerity, Avonex, Plegridy, Spinraza, Skyclarys, Qalsody. Biogen books the gross product revenue and bears all SG&A.
- Profit-sharing collaborations – Leqembi (lecanemab) with Eisai: Eisai leads global commercialisation; Biogen and Eisai share net profits and losses 50/50 worldwide. Biogen reports its share through the “Leqembi” revenue line and an offsetting cost-of-sales / SG&A allocation. Zurzuvae (zuranolone) is co-promoted in the U.S. with Sage Therapeutics (now part of Supernus); Biogen books revenue and pays Supernus 50% of net product revenue.
- Royalty & contract manufacturing – royalties on Genentech/Roche’s Ocrevus and Rituxan (originated from the Idec heritage) and contract-manufacturing services for third-party biologics from Biogen’s plants in RTP (NC) and Switzerland.
- Biosimilars – Benepali (etanercept), Imraldi (adalimumab) and Flixabi (infliximab) sold mainly in Europe through the Samsung Bioepis joint venture (Biogen sold its equity stake in Samsung Bioepis in 2022 but retains commercial rights in certain regions).
Capital allocation under Christopher Viehbacher has prioritised business development over buybacks: the Reata acquisition ($7.3 bn, closed 2023, brought Skyclarys), HI-Bio (~$1.15 bn upfront in 2024, brought felzartamab), and now the pending Apellis deal (~$5.6 bn enterprise value plus CVRs) take precedence over share repurchases.
5. Financial Health
Five-year revenue trend (FY 2021–FY 2025), USD billions: 10.98 → 10.17 → 9.84 → 9.68 → 9.89. Revenue troughed in 2024 and returned to modest growth (+2%) in 2025 as launch products outpaced MS erosion.
Quarterly revenue and Non-GAAP gross margin (last five quarters):
| Quarter | Revenue ($bn) | Non-GAAP gross margin | Non-GAAP diluted EPS |
|---|---|---|---|
| Q4 2024 | 2.45 | ~79% | 3.44 |
| Q1 2025 | 2.43 | ~78% | 3.02 |
| Q2 2025 | 2.80 | ~80% | 5.25 |
| Q3 2025 | 2.54 | ~79% | 4.81 |
| Q4 2025 | 2.28 | ~80% | 1.99 |
Cash, debt and free cash flow: at 31 December 2025 Biogen held $4.2 bn cash and marketable securities against $6.3 bn of total debt, leaving net debt of ~$2.0 bn. Free cash flow for FY 2025 was $2.05 bn. The pending Apellis transaction ($5.6 bn cash plus CVRs) will be funded with a combination of existing cash and new debt, materially increasing leverage during 2026.
6. Valuation & Market Data
| Share price (24 Apr 2026) | $184.38 |
| Market cap | ~$27.1 bn |
| Enterprise value | ~$29.1 bn |
| Trailing P/E (GAAP) | ~21× |
| Trailing P/E (Non-GAAP) | ~12× |
| Forward P/E (Non-GAAP, FY26 mid-point $15.75) | ~11.7× |
| Price/Sales | ~2.7× |
| EV/EBITDA (TTM) | ~7.2× |
| P/FCF | ~13× |
| 52-week range | $115.25 – $202.41 |
| Short interest | ~3.34 m shares (~2.3% of float) |
| Dividend | None |
| Average daily volume (3-month) | ~1.30 m shares |
No analyst price targets or buy/sell/hold ratings are referenced; investors should form their own view from the data above.
7. What Are They Building / What’s Coming?
Biogen’s clinical pipeline now spans Alzheimer’s, neuromuscular disease, immunology, lupus and rare nephrology. Selected late-stage and near-term catalysts:
| Asset | Indication | Stage / next catalyst |
|---|---|---|
| Leqembi IQLIK (lecanemab SC) | Early Alzheimer’s – subcutaneous maintenance | FDA PDUFA 24 May 2026 (Priority Review) |
| BIIB080 (tau ASO) | Alzheimer’s | Phase 2 CELIA readout expected mid-2026; FDA Fast Track |
| Salanersen (next-gen nusinersen) | SMA | Phase 1b interim data positive; Phase 3 starting 2026 |
| Felzartamab (anti-CD38) | IgA nephropathy, antibody-mediated transplant rejection, primary membranous nephropathy | Three Phase 3 trials; first readout H1 2027 |
| Dapirolizumab pegol | Systemic lupus erythematosus (with UCB) | Phase 3 positive; regulatory submissions planned |
| Litifilimab (anti-BDCA2) | Cutaneous & systemic lupus | Phase 3 ongoing |
| Zurzuvae | Postpartum depression – ex-US expansion | EU approval Sep 2025; Health Canada approval Dec 2025 |
| High-dose Spinraza | SMA | FDA approved 30 March 2026; EU CHMP positive opinion April 2026 |
| Empaveli & Syfovre (via Apellis) | Rare kidney disease, PNH, geographic atrophy | Apellis acquisition closing Q2 2026 |
8. Competitive Landscape
The most-watched competitive battle is in early symptomatic Alzheimer’s, where Biogen/Eisai’s Leqembi faces Eli Lilly’s Kisunla (donanemab). As of Q4 2025 reported in-market sales were:
- Leqembi (Eisai/Biogen) – ~$134 m global, ~$78 m U.S.
- Kisunla (Eli Lilly) – ~$109 m, U.S.-led
Industry trackers put Leqembi at roughly 60% of cumulative U.S. anti-amyloid prescriptions but Kisunla took roughly 50% of new starts by year-end 2025 thanks to monthly (not biweekly) infusion and a defined treatment-stop option once amyloid clears. The launch of Leqembi IQLIK (subcutaneous, weekly maintenance, PDUFA 24 May 2026) is the key counter-move.
Other key competitive fronts:
- Multiple sclerosis – Roche’s Ocrevus (anti-CD20) continues to take share in relapsing MS; Novartis’s Kesimpta (subcutaneous anti-CD20) and Sanofi’s tolebrutinib (BTK) loom; Tecfidera and Tysabri face generic and biosimilar erosion (Tyruko biosimilar to Tysabri is on the U.S./EU markets).
- Spinal muscular atrophy – Roche’s oral Evrysdi (~$2.0 bn 2025 sales) is now the SMA market leader; Novartis’s gene therapy Zolgensma (~$1.2 bn) competes in infants. Spinraza fell to ~$1.55 bn; high-dose Spinraza is the defensive response.
- Friedreich’s ataxia – Skyclarys remains the only approved disease-modifier; emerging gene therapy programmes from Larimar (CTI-1601) and others are in earlier clinical stages.
- Postpartum depression – Zurzuvae faces broader generic SSRI/SNRI use; positioning rests on rapid 14-day onset.
- Immunology / nephrology (post Apellis & HI-Bio) – competes with Vertex (povetacicept), Travere (sparsentan), Novartis (atrasentan, iptacopan) and AbbVie/J&J in IgA nephropathy and PNH.
9. Leadership and Ownership
Key executives:
| President & CEO | Christopher Viehbacher (since Nov 2022; previously CEO of Sanofi) |
| EVP & CFO | Robin Kramer (CFO since March 2025; joined Biogen 2018) |
| EVP & Head of Development | Priya Singhal, M.D., M.P.H. |
| Chief Medical Officer | Maha Radhakrishnan, M.D. |
| Head of North America Commercial | Alisha Alaimo |
| Chair of the Board | Stelios Papadopoulos, Ph.D. |
Top institutional holders (latest 13F filings):
| Holder | Approx. % of shares outstanding |
|---|---|
| The Vanguard Group | ~11.0% |
| PRIMECAP Management | ~11.0% |
| BlackRock | ~8.5% |
| FMR (Fidelity) | ~5% |
| State Street | ~4% |
| Total institutional ownership | ~88–90% |
Selected recent insider transactions:
| Date | Insider | Transaction | 10b5-1? |
|---|---|---|---|
| 13 Feb 2026 | Christopher Viehbacher (CEO) | Grant of 38,015 RSUs vesting in three equal annual tranches | N/A – equity grant |
| 2025 | Priya Singhal (Head of Development) | Open-market sale of ~$134k of stock | Reported under standard Form 4 |
Data gap: a complete 12-month rolling list of Form 4 filings broken out by 10b5-1 designation is not provided in the public summaries reviewed; readers should consult the Biogen SEC filings page for the full record.
10. Risks and Challenges
- MS franchise erosion – Tecfidera generics, Tysabri biosimilars (Tyruko) and Ocrevus competition continue to compress the largest revenue bucket; the Genentech royalty judgment cost Biogen a one-off charge in FY 2025.
- Leqembi competition & access – Kisunla’s monthly dosing and stop-rule are taking share at the launch margin; CMS reimbursement requires PET/CSF amyloid confirmation and infusion-centre capacity, slowing penetration; ARIA safety monitoring remains a clinical hurdle.
- Spinraza decline – even with the new high-dose regimen, Roche’s oral Evrysdi and Novartis’s Zolgensma continue to take new-patient starts.
- Pipeline binary risk – the “new Biogen” thesis hinges on multiple readouts: BIIB080 tau ASO Phase 2 mid-2026, dapirolizumab regulatory path, felzartamab Phase 3 first readouts in 2027.
- M&A integration & leverage – the $5.6 bn Apellis acquisition adds debt and execution risk; integration of three commercial brands plus a sales force into Biogen at the same time as the Reata, HI-Bio and Sage zuranolone assets are still being absorbed is non-trivial.
- Macro/policy – U.S. drug pricing reform under the Inflation Reduction Act (Spinraza is among the early candidates for IRA negotiation), potential tariffs on biopharma imports, and FX volatility for ex-US sales.
- Patent cliffs – Tysabri composition-of-matter and key MS patents have expired; biosimilar entrants are actively eroding these markets.
11. Recent Developments
Last 48 hours:
- 25 Apr 2026 – Goldman Sachs raised its Biogen price target from $231 to $238 (Buy rating maintained); Rothschild & Co Redburn lifted target from $150 to $180 (Neutral); shares closed at $184.38 on 24 April with volume below the three-month average.
- 23 Apr 2026 – UBS upgraded Biogen from Neutral to Buy with a $225 price target ahead of Q1 2026 earnings, citing a 12-month “catalyst parade”.
Last six months:
- 20 Apr 2026 – Biogen agreed to acquire TJ Biopharma’s Greater China rights to felzartamab for $100 m upfront and up to $750 m in milestones (total $850 m), giving Biogen worldwide rights.
- 3 Apr 2026 – FDA approved Biogen’s licensing-related IPR&D activity (Q1 2026 IPR&D charge guided at ~$34 m / $0.19 EPS impact).
- 31 Mar 2026 – Biogen agreed to acquire Apellis Pharmaceuticals for ~$5.6 bn ($41.00 per share cash, ~140% premium, plus a $4 CVR), adding Empaveli (rare kidney disease, PNH) and Syfovre (geographic atrophy). Apellis booked $689 m of revenue in 2025; deal expected to close in Q2 2026.
- 30 Mar 2026 – FDA approved high-dose Spinraza regimen for SMA; loading phase reduced from four to two doses.
- April 2026 – CHMP issued positive opinion on high-dose nusinersen in EU; European Commission decision expected in Q2 2026.
- 13 Feb 2026 – CEO Christopher Viehbacher granted 38,015 RSUs (annual long-term incentive grant).
- 6 Feb 2026 – Q4 / FY 2025 results: revenue $9.89 bn (+2%); growth products +19% to $3.3 bn; Non-GAAP EPS $15.28; FY 2026 EPS guidance $15.25–$16.25; revenue down mid-single-digit %.
- Late 2025 – Zurzuvae approved by European Commission (Sep 2025) and Health Canada (Dec 2025) for postpartum depression; Leqembi IQLIK (subcutaneous maintenance) BLA approved in U.S. August 2025; Skyclarys patient base grew ~30% in 2025.
12. Key Dates Coming Up
| Date | Event |
|---|---|
| 29 April 2026 (pre-market) | Q1 2026 earnings release & conference call |
| 24 May 2026 | FDA PDUFA – Leqembi IQLIK subcutaneous formulation |
| Q2 2026 | Expected closing of Apellis acquisition |
| Q2 2026 | European Commission decision on high-dose Spinraza (post CHMP positive opinion) |
| Mid-2026 | BIIB080 (tau ASO) Phase 2 CELIA topline data in early Alzheimer’s |
| Late August 2026 | FDA PDUFA – Leqembi subcutaneous maintenance dosing |
| 2H 2026 | Q2 2026 earnings (typically late July / early August) |
| H1 2027 | First Phase 3 felzartamab readout (initial nephrology indication) |
| n/a | No dividend – no ex-dividend date |
Explore further on ChartsView:
Disclaimer: This research note is prepared for educational and informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. ChartsView and its authors are not registered investment advisers. All financial figures are sourced from Biogen press releases, SEC filings, partner disclosures (Eisai, Apellis, BioArctic) and reputable financial media as of 26 April 2026 and may be subject to revision. Investors should perform their own due diligence and consult an authorised financial adviser before making investment decisions. Pharmaceutical investing carries the additional risk that clinical-trial outcomes, regulatory decisions and reimbursement determinations can move share prices materially in either direction.
Loading research report…
13. Thesis Verdict
The central thesis. The report describes a mixed financial trajectory across the last five years with peer-comparable positioning on structural metrics. A dated catalyst within the next month will provide the nearest test of management guidance. The bull case and bear case presented by the report carry broadly comparable weight on the evidence compiled here.
What would confirm or break it. Recent news flow has been net-positive with a limited number of high-severity risks disclosed. Subsequent earnings landing in line with or above management guidance would reinforce the thesis; materialisation of the top disclosed risk — or any filing that fundamentally alters the growth or capital-return profile — would invalidate it. The deterministic rule engine classifies this evidence base as moderate.
Watchpoints
- InvalidatesMaterialisation of the "Pipeline binary risk" risk, or any disclosure that fundamentally alters the capital-return or growth profile stated by management.
- ConfirmsSubsequent earnings and filings reinforcing the figures presented in this report.
- InvalidatesAny disclosure that directly contradicts a material claim in the bull case.
Diagnostic grid
Generated by ChartsView research tooling (rule-derived summary — LLM unavailable). Thesis strength measures how well the evidence in this report supports the company's stated thesis — it is NOT a buy/sell rating or price target. ChartsView is not authorised by the FCA to provide regulated investment advice. Generated 26 Apr 2026.